The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Patient selection for transcatheter edge-to-edge mitral valve repair for severe functional mitral regurgitation

EuroIntervention 2020;16:367-369. DOI: 10.4244/EIJV16I5A67

1. Baylor University Medical Center, Baylor Heart and Vascular Institute, Cardiology Section, Dallas, TX, USA
In 2018, two randomised clinical trials of transcatheter edge-to-edge mitral valve repair (TMVr) for functional mitral regurgitation (FMR) reported very different outcomes. The MITRA-FR trial showed no statistically significant difference in the combined endpoint of death or hospitalisation for heart failure (HF) at one year1. The COAPT trial showed marked improvements in total HF hospitalisations at two years, as well as mortality and multiple other pre-specified secondary endpoints2. We hypothesised that the divergent outcomes of the two trials could be explained largely by enrolment of different patient populations3. Patients in COAPT had a larger mean effective regurgitant orifice area (EROA) and ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores